MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

    J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)

    Objective: Evaluate efficacy/safety of levodopa-carbidopa intestinal gel (LCIG) daytime monotherapy (with/without nighttime oral carbidopa/levodopa) vs polytherapy (LCIG with >1 adjunctive therapy) in advanced Parkinson’s disease…
  • 2018 International Congress

    Patient’s Choice of Device-Based Treatments in Parkinson’s Disease

    M. Kuzu Kumcu, S. Tezcan Aydemir, Ç. Ulukan, B. Bakırarar, C. Akbostancı (Ankara, Turkey)

    Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…
  • 2018 International Congress

    Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease

    I. Mironova, A. Latypova, I. Zhukova, O. Izhboldina, E. Kolupaeva, N. Zhukova, S. Ivanova (Tomsk, Russian Federation)

    Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…
  • 2018 International Congress

    Long Term Response to L-dopa in Parkinson Disease

    H. Gupta, N. Wachter, K. Lyons, R. Pahwa (Kansas, KS, USA)

    Objective: To assess the long-term effectiveness of levodopa in Parkinson’s disease (PD) patients. Background: To date, levodopa continues to be the most efficacious drug in…
  • 2018 International Congress

    Treatment with levodopa/carbidopa intestinal gel of advanced Parkinson’s disease patients: Bulgarian experience

    E. Chorbadzhieva (Sofia, Bulgaria)

    Objective: To evaluate the efficacy of levodopa/carbidopa intestinal gel (LCIG) on motor fluctuations, dyskinesia, parkinson symptoms and quality of life in patients with late Parkinson’s…
  • 2018 International Congress

    Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

    J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

    Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…
  • 2018 International Congress

    Impact of STN-DBS on Medication Reduction

    M. Carmona-Abellán, G. de Ulibarri, J. Guridi, P. Clavero, M. Alegre, R. Luquin-Piudo (Pamplona, Spain)

    Objective: We aim to evaluate the efficacy of subthalamic nucleus deep brain stimulation on reducing medication in Parkinson´s disease patients. Background: Parkinson's disease (PD) is…
  • 2018 International Congress

    Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

    HS. Yoo, SJ. Chung, BS. Ye, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

    Objective: To investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of levodopa-induced dyskinesia (LID) onset in Parkinson's disease (PD). Background:…
  • 2018 International Congress

    Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period

    A. Azimov, R. Sadykov, G. Rakhimbaeva, F. Azimov (Tashkent, Uzbekistan)

    Objective: To study the possibility of using dopaminergic medicines for the treatment of Bell`s paralysis in acute period. Background: In previous reports we conjectured that…
  • 2018 International Congress

    Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa-Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson’s Disease. ADEQUA Study

    F. Valldeoriola, M.J. Catalán, F. Escamilla-Sevilla, E. Freire, J. Olivares, E. Cubo, D. Santos, J.C. Parra, G. Arroyo, J.M. Arbelo (Barcelona, Spain)

    Objective: The primary objective of the present study was to assess the effect of levodopa-carbidopa intestinal gel (LCIG) on the QoL of patients with advanced…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley